AI assistant
Immuron Ltd — AGM Information 2020
Sep 29, 2020
35121_rns_2020-09-29_270cdf58-d642-4e68-a274-7b7af706a8c3.pdf
AGM Information
Open in viewerOpens in your device viewer
==> picture [202 x 56] intentionally omitted <==
Time of AGM Clarification
Melbourne, Australia, September 30, 2020: Immuron Limited (ASX: IMC; NASDQ: IMRN), would like to clarify the time that the Company’s Annual General Meeting (AGM) will be held as disclosed on the Notice of 2020 AGM previously released.
Date of Meeting: Thursday, 29[th] October 2020 Time of Meeting ( Melbourne, Australia time ): 4:30pm (Registration from 4:15pm)
Date of Meeting:
All else being the same.
- - - END - - -
COMPANY CONTACT:
Phillip Hains
Company Secretary Ph: +61 (0)3 9824 5254 [email protected]
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel and safe technology platform with one commercial asset generating revenue. In Australia, Travelan® is a listed medicine on the Australian Register of Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travellers’ Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licenced natural health product (NPN 80046016) and is indicated to reduce the risk of Travellers’ Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection in accordance with section 403 (r)(6) of the Federal Drug Administration (FDA).
For more information visit: http://www.immuron.com
==> picture [607 x 64] intentionally omitted <==